PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22534775-7	2012	However, the assay with the addition of exogenous antithrombin detected falsely high concentrations of rivaroxaban even in plasma samples from controls who had not taken rivaroxaban (intercept values using the high calibrator set and the low calibrator set: +26.49 ng/ml and +13.71 ng/ml, respectively).	Rivaroxaban	103-114	serpin family C member 1	Homo sapiens	50-62	
25869030-0	2015	Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment.	Rivaroxaban	26-37	serpin family C member 1	Homo sapiens	108-120	
32039550-6	2020	RESULTS: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin-supplemented anti-Xa method (Berichrom).	Rivaroxaban	63-74	serpin family C member 1	Homo sapiens	89-101	
21655672-8	2011	The AT assay dependent on thrombin activity was not influenced by rivaroxaban, whereas the AT levels dependent on factor Xa activity were significantly increased by rivaroxaban.	Rivaroxaban	165-176	serpin family C member 1	Homo sapiens	91-93	
20946166-4	2011	MATERIALS AND METHODS: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0-1000 mug L(-1) and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays.	Rivaroxaban	23-34	serpin family C member 1	Homo sapiens	232-244	
19170587-4	2009	Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa.	Rivaroxaban	0-11	serpin family C member 1	Homo sapiens	203-215	
29526957-6	2018	Rivaroxaban (15 mg) was continued for 6 months with no recurrence, indicating the efficacy of this factor Xa inhibitor for the treatment and prevention of VTE in patients with antithrombin deficiency.	Rivaroxaban	0-11	serpin family C member 1	Homo sapiens	176-188	
28888219-10	2018	CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.	Rivaroxaban	29-40	serpin family C member 1	Homo sapiens	84-96	
28888219-10	2018	CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation.	Rivaroxaban	107-118	serpin family C member 1	Homo sapiens	84-96	
30279820-8	2017	The present case suggests that rivaroxaban is a direct Factor Xa inhibitor and does not require cofactors such as antithrombin-III, thus it is suitable for anticoagulation therapy in patients with low antithrombin-III activity.>.	Rivaroxaban	31-42	serpin family C member 1	Homo sapiens	201-217	
28794370-5	2017	The present case illustrates the effectiveness of rivaroxaban in preventing thromboembolisms due to surgery, even in very elderly patients with antithrombin deficiency.	Rivaroxaban	50-61	serpin family C member 1	Homo sapiens	144-156